KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin (2016 - 2026)

TherapeuticsMD filings provide 16 years of EBT Margin readings, the most recent being 14.23% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 18420.0% to 14.23% in Q1 2026 year-over-year; TTM through Mar 2026 was 3.52%, a 12313.0% increase, with the full-year FY2025 number at 21.61%, up 11144.0% from a year prior.
  • EBT Margin hit 14.23% in Q1 2026 for TherapeuticsMD, up from 64.95% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 70.67% in Q4 2022 to a low of 4273.85% in Q2 2022.
  • Median EBT Margin over the past 5 years was 258.47% (2024), compared with a mean of 940.74%.
  • Biggest five-year swings in EBT Margin: crashed -408842bps in 2022 and later skyrocketed 372145bps in 2023.
  • TherapeuticsMD's EBT Margin stood at 70.67% in 2022, then plummeted by -547bps to 315.54% in 2023, then surged by 104bps to 12.44% in 2024, then crashed by -622bps to 64.95% in 2025, then skyrocketed by 122bps to 14.23% in 2026.
  • The last three reported values for EBT Margin were 14.23% (Q1 2026), 64.95% (Q4 2025), and 6.38% (Q3 2025) per Business Quant data.